Amylyx Pharmaceuticals, Inc. AMLX Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Research And Development Expense Excluding Acquired In Process Cost by Product | |||
| AMX0035PSP | $17.26M+2.0% | $16.92M+164% | |
| Avexitide | $24.1M+771% | $2.77M— | |
| Other Programs | $15.47M+74.7% | $8.86M-36.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Amylyx Pharmaceuticals, Inc. break its business down?
- Amylyx Pharmaceuticals, Inc. (AMLX) reports research and development expense excluding acquired in process cost by product across 3 parts — AMX0035PSP, Avexitide and Other Programs. Each is extracted from the segment footnotes and tracked over time.
- Where does Amylyx Pharmaceuticals, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amylyx Pharmaceuticals, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.